PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
32.68%
Net income growth 1.25-1.5x AVXL's 26.17%. Bruce Berkowitz would verify whether cost discipline or revenue gains drive the outperformance.
80.19%
D&A growth of 80.19% while AVXL is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
-398.37%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
30.65%
SBC growth while AVXL is negative at -39.64%. John Neff would see competitor possibly controlling share issuance more tightly.
27.89%
Slight usage while AVXL is negative at -110.15%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-35.29%
Negative yoy AP while AVXL is 0.00%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
66.06%
Some yoy usage while AVXL is negative at -110.15%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
30.65%
Some yoy increase while AVXL is negative at -100.12%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-19.98%
Both yoy CFO lines are negative, with AVXL at -126.54%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-32.37%
Negative yoy CapEx while AVXL is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-271.58%
We reduce yoy invests while AVXL stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
69.11%
Debt repayment growth of 69.11% while AVXL is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
-69.14%
Both yoy lines negative, with AVXL at -80.78%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.